Prolight Diagnostics
0.133 SEK -6.34%Be the first to follow this company
Prolight Diagnostics develops test systems in POCT (Point of care testing). The tests are used outside of hospital laboratories to enable rapid assessments of the health of patients. The company's POCT platform is under development with the intention of measuring various biomarkers simultaneously. An important component of the work is to reduce the time for test results, particularly important for patients with heart problems. The company was founded in 1999 and is based in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Nordic SME
PRLD
Daily low / high price
0.124 / 0.14
SEK
Market cap
66.47M SEK
Turnover
554.78K SEK
Volume
4.2M
Financial calendar
Interim report
2024-08-28
Interim report
2024-11-27
Annual report
2025-02-21
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 4.9 % | 4.9 % |
The Bank of New York Mellon, W9 | 4.0 % | 4.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Prolight Diagnostics publishes quarterly report Q1, 2024
Prolight Diagnostics tilldelas statligt brittiskt bidrag om 17 MSEK i samarbete med ledande brittisk sjukhussammanslutning
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools